About Us | Contact Us |        

Optimizing Patient Outcomes Through Stem Cell Mobilization

Hematology-Oncology
Curriculum:
Successful Stem Cell Mobilization Strategy
Credits:
1 AMA PRA Category 1 Credit(s)™
Launch Date:
December 20, 2013
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Hematologist-oncologists, Medical oncologists, Oncology Nurses, Other healthcare professionals

Relevant Terms:

Hematopoietic Stem Cell Transplantation, Multiple Myeloma, Non-Hodgkin's Lymphoma, Stem Cell Mobilization

William I. Bensinger, MD

William I. Bensinger, MD
University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
Seattle, WA

Dr. William Bensinger is Director of the Autologous Stem Cell Transplant Program at the Fred Hutchinson Cancer Research Center, Seattle, WA. He is a Full Member at the Center and Professor of Medicine at the University of Washington, Seattle, WA.  He has published more than 200 articles in refereed journals, books, and monographs in the field of stem cell transplantation on the subjects of mobilization, collection, and transplantation of autologous and allogeneic stem cells, especially as it relates to the treatment of multiple myeloma. Other publications include the use of CD34 selected stem cells and innovative transplant regimens. Dr. Bensinger holds several patents, including as co-inventor of the avidin-biotin bead selection system. He is a member of the NCCN myeloma guidelines committee and a co-chair of the NCCN cancer related infection guidelines committee. He is also a member of the Intl Myeloma Working Group clinical endpoints committee.

William I. Bensinger, MD, reported a financial interest/relationship or affiliation in the form of: Advisory Board, Celgene Corporation, Millennium Pharmaceuticals, Inc.; Speakers' Bureau, Celgene Corporation; Contracted Research, Acetylon Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., Pharmacyclics, Inc., sanofi US.

Sergio A. Giralt, MD

Sergio A. Giralt, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

Sergio A. Giralt, MD is the Chief of the Adult Bone Marrow Transplant Service in the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center in New York, New York. He is affiliated with Weill Cornell Medical College as a Professor of Medicine. He received his medical degree from Universidad Central de Venezuela in Caracas, Venezuela, and completed his postgraduate internship at the University Hospital of Caracas. He also completed an internal medicine residency at Good Samaritan Hospital in Cincinnati, Ohio, and a postdoctoral fellowship in hematology and oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Giralt holds membership in several professional societies, including the American Society of Hematology, the American Society of Clinical Oncology, the North American Society of Blood and Bone Marrow Transplantation, and the International Society of Hematology. He is the President-Elect of the American Society for Blood and Marrow Transplantation, as well as the Past Chair of the Blood and Marrow Transplant Clinical Trials Network and of the Center for International Blood and Marrow Transplant Research. Dr. Giralt has published over 400 articles and abstracts in peer-reviewed literature and written chapters for several books.

Sergio A. Giralt, MD, reported a financial interest/relationship or affiliation in the form of: Advisory Board, BioLineRx, Celgene Corporation, Janssen Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., sanofi US, Seattle Genetics, Inc., Skyline Diagnostics, Spectrum Pharmaceuticals, Inc.; Contracted Research, Celgene Corporation.
1. Utilize individual patient characteristics to select the best method for stem cell mobilization in patients with multiple myeloma and lymphoma
2. Discuss the role, clinical importance, and appropriate timing of stem cell mobilization prior to transplantation
3. Evaluate current and emerging stem cell mobilization regimens available for patients undergoing stem cell transplantation
4. Implement treatment strategies to effectively mobilize stem cells for successful transplantation
5. Assess the role of ASCT in the treatment of patients with multiple myeloma and lymphoma
6. Implement effective side effect management strategies to optimize outcomes in patients undergoing stem cell mobilization and transplant

COURSE VIEWING REQUIREMENTS

Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

 
 
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through joint sponsorship of Postgraduate Institute for Medicine and AXIS. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

William I. Bensinger, MD, reported a financial interest/relationship or affiliation in the form of: Advisory Board, Celgene Corporation, Millennium Pharmaceuticals, Inc.; Speakers' Bureau, Celgene Corporation; Contracted Research, Acetylon Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., Pharmacyclics, Inc., sanofi US.

Sergio  A. Giralt, MD, reported a financial interest/relationship or affiliation in the form of: Advisory Board, BioLineRx, Celgene Corporation, Janssen Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., sanofi US, Seattle Genetics, Inc., Skyline Diagnostics, Spectrum Pharmaceuticals, Inc.; Contracted Research, Celgene Corporation.

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Linda Gracie-King, MS and Jocelyn Timko, BS, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

SAFEGUARDS AGAINST COMMERCIAL BIAS
Postgraduate Institute of Medicine and AXIS affirm that the content and format of its CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute of Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute of Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education's content validation statements and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:
  1. Fair balance
    a. Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
    b. No single product or service is overrepresented when other equal competing products or services are available for inclusion
  2. Scientific objectivity of studies mentioned in the materials or used as the basis for content
  3. Appropriateness of patient care recommendations made to learners

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION
To receive acknowledgement of participation for this CME-certified activity, you must complete the evaluation and pass the posttest online with a score of 65% or better in a maximum of 5 attempts. You may print and/or download your certificate upon completion.

ESTIMATED TIME TO COMPLETE ACTIVITY: 1-hour

FEE STATEMENT
There is no fee for this educational activity.

CONTACT INFORMATION
To contact PIM, please visit www.pimed.com.

Jointly sponsored by:


 
Supported through an educational grant from sanofi-aventis U.S.